Glioma patients with IDH1 hotspot mutations are known to have better survival than those without such mutations [11,24,32], but astrocytoma patients with non-canonical IDH1R132X have even longer survival than those with IDH1R132H [33]. Here, IDH1 is linked to astrocytoma (excluding glioblastoma).